{"id":"losartan-and-nebivolol","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor antagonist that blocks vasoconstriction and aldosterone secretion, lowering blood pressure. Nebivolol is a selective beta-1 adrenergic blocker with vasodilatory properties that reduces heart rate and cardiac workload. Together, they provide complementary antihypertensive effects through different mechanisms.","oneSentence":"This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and slowing heart rate through beta-1 adrenergic blockade (nebivolol).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:29.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT02817360","phase":"PHASE4","title":"NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients","status":"RECRUITING","sponsor":"Martin Huelsmann","startDate":"2016-02","conditions":"Heart Diseases, Diabetes Mellitus, Type 2","enrollment":2400},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00673790","phase":"PHASE4","title":"The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-05-15","conditions":"Hypertension","enrollment":537},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT00683124","phase":"PHASE3","title":"Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2008-07","conditions":"Marfan Syndrome","enrollment":291},{"nctId":"NCT00734630","phase":"PHASE4","title":"Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Hypertension","enrollment":491}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Losartan and nebivolol","genericName":"Losartan and nebivolol","companyName":"Fondazione IRCCS Policlinico San Matteo di Pavia","companyId":"fondazione-irccs-policlinico-san-matteo-di-pavia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and slowing heart rate through beta-1 adrenergic blockade (nebivolol). Used for Hypertension, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}